米拉制药公司的药物Ketamir-2逆转了动物体内的创伤后精神紧张症症状,并可能进入人类试验阶段。 Mira Pharmaceuticals' drug Ketamir-2 reversed PTSD symptoms in animals and may advance to human trials.

MIRA制药公司报告说,其口服药物候选者Ketamir-2在经证实的创伤后精神紧张症模式下恢复了动物的正常行为,扭转了绝望和避免等与压力有关的症状。 MIRA Pharmaceuticals reports that its oral drug candidate Ketamir-2 restored normal behavior in animals within a validated PTSD model, reversing stress-related symptoms like despair and avoidance. 根据第一阶段神经病痛试验提供的有希望的安全数据,这些结果支持扩大对包括创伤后精神紧张症在内的神经精神紊乱的评价。 The results support expanding evaluation into neuropsychiatric disorders, including PTSD, following promising safety data from a Phase 1 trial for neuropathic pain. 该公司计划探索与军事和政府实体的合作,以解决未得到满足的对有效创伤后精神紧张症治疗的大量需求,并正在进行一项更大的后续研究。 The company plans to explore collaborations with military and government entities to address the significant unmet need for effective PTSD treatments, with a larger follow-on study underway.